Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

GERN News and Commentary

View All GERN News and Commentary

Caps

How do you think GERN will perform against the market?

Add Stock to CAPS Watchlist

All Players

644 Outperform
63 Underperform
 

All-Star Players

85 Outperform
19 Underperform
 

Wall Street

8 Outperform
2 Underperform
 

Top GERN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

manirg (< 20)
Submitted August 06, 2015

undervalued, high potential

zzlangerhans (99.82)
Submitted August 16, 2013

Geron spiked up a little on rather vague descriptions of progress made in the IST of imetelstat for myelofibrosis but I maintain this one surviving indication for one surviving pipeline candidate doesn't merit an enterprise value of more than 100M.

GERN VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about GERN.

Recs

0
Member Avatar TMFang4apples (56.58) Submitted: 8/17/2017 9:30:37 AM : Outperform Start Price: $2.07 GERN Score: +7.17

I think imetelstat has a much better shot than Geron's market cap suggests.

Recs

0
Member Avatar marsuculix (41.76) Submitted: 3/6/2017 9:17:07 AM : Outperform Start Price: $2.20 GERN Score: -2.99

takeover candidate

Recs

0
Member Avatar pbookidis (< 20) Submitted: 3/2/2017 9:57:43 PM : Outperform Start Price: $2.20 GERN Score: -2.70

good results will prevail FDA tests prevailing.

Leaderboard

Find the members with the highest scoring picks in GERN.

Score Leader

Ravelin

Ravelin (78.80) Score: +412.10

The Score Leader is the player with the highest score across all their picks in GERN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
SheepInvstr213 < 20 3/9/2009 Underperform 5Y $4.59 -51.22% +270.46% +321.68 0 Comment
epc53 28.02 3/3/2009 Underperform NS $3.85 -41.82% +259.45% +301.27 0 Comment
Dudeone 83.60 3/12/2009 Underperform 5Y $4.32 -48.15% +240.40% +288.55 0 Comment
js2776 < 20 1/26/2009 Underperform 3Y $8.15 -72.52% +202.72% +275.24 2 Comments
kevleeyang 71.67 1/23/2009 Underperform NS $7.23 -69.02% +205.61% +274.63 0 Comment
yourfavoritepers 92.37 1/26/2009 Underperform 3W $7.47 -70.01% +203.05% +273.06 0 Comment
Lafleur526 42.96 1/26/2009 Underperform 3W $7.47 -70.01% +203.05% +273.06 0 Comment
dcfoolz 71.83 1/26/2009 Underperform 5Y $7.47 -70.01% +203.05% +273.06 0 Comment
SheepInvstr321 94.23 1/23/2009 Underperform 5Y $7.36 -69.56% +202.54% +272.11 0 Comment
e2003 96.77 3/30/2009 Underperform 1Y $4.75 -52.84% +215.46% +268.30 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 86.71 8/12/2013 Outperform NS $1.59 +40.88% +47.77% -6.89 0 Comment
TrackPiperJaff 86.71 1/18/2013 Outperform NS $1.78 -30.90% +5.76% -36.66 3/14/2013 @ $1.23 0 Comment
TrackPoisedTo < 20 8/31/2012 Underperform 5Y $2.64 -15.15% +76.18% +91.34 0 Comment
TrackStifel 94.51 8/30/2012 Outperform NS $2.57 -12.84% +76.67% -89.51 0 Comment
trackwbbsecuriti < 20 11/16/2011 Outperform NS $1.68 +33.33% +99.45% -66.11 0 Comment
TrackRodmanRen < 20 1/23/2009 Outperform NS $7.04 -68.18% +211.59% -279.77 0 Comment
trackmerriman 74.17 12/11/2008 Outperform NS $4.29 -47.79% +182.25% -230.03 0 Comment
TrackUBS 93.35 1/29/2008 Outperform NS $5.00 -55.20% +90.62% -145.82 0 Comment
TrackEveillard 95.86 9/30/2007 Outperform NS $7.32 -69.40% +70.93% -140.33 2 Comments
TrackTobinSmith < 20 11/11/2006 Outperform 1Y $8.59 -73.92% +91.13% -165.05 0 Comment
TrackJimCramer 84.63 3/24/2006 Underperform 3W $8.33 -73.11% +104.86% +177.97 0 Comment

Featured Broker Partners